Member Info for PM2022

Cash burn is very high here and they have nothing really to justify such a large market cap. I doubt they will get a 7 figure deal and even if they did it would still have to go a long way before justifying such a large market cap.

I see this dropping to a 5 million market cap unless they actually get decent money coming through and lowering the cash burn rate. By the time that happens they will likely need a massive placing.

He sees no opportunity at this very low market cap which proves he has little left after the 4D disaster. Just here because it makes him feel better.

If they get a deal through by year end this can bounce back massively but it could go the other way as well but I don't think the drop will be significant at this price. It comes down to how the BOD manages the situation.

Fairly certain if a raise was needed it would be oversubscribed if they back it at these prices. It would surprise me if they never purchased a large amount.

I would give a 10% discount. If you do not take it at this price and market cap then you are unlikely to take it. Issuing more shares than necessary creates more negativity from existing holders in the longer run. I am sure the demand will be high with a bit more clarity.

Still at this price with plenty of news to come including StingyRay outcome then we could anywhere in the next few weeks.

What goes up goes down and what goes down goes up.

Valirx when it moves tends to move big. In the 4 years or so it has gone from 3p to 74p in a few weeks and 6p to 65p and back down. History often repeats.

All those being negative were doing the same back then. I think Valirx has significant potential and as we know both 201 and 401 deals remain in play before year end and who knows we may get a decent update on CLX which I think is not far away.

Porky please enjoy your Sunday rather than spending all day on LSE.

Regarding the points about 201, if the trial was larger then the deal size and potential upfront payments could have reached tens of millions with much higher milestones. However, the main advantage of larger trials is to obtain better datasets. For investors, the main factor is whether the deal is concluded. The data in the previous trial showed promise but it needs more work which is the reason why they have phase 2b trials.

With a market cap of just over a million, the initial payments for 201 exceed that amount, not to mention the potential £65 million. THe Valirx share price went to 65p and 74p following the trial results and the letter of intent, so if this deal concludes, it could lead to serious multibagging. 401 seems more promising with a potential 15 million for a single trial completion, and with several lab contracts in place, they could start generating decent revenue. I see significant potential in the coming months.

Again this is similar to when it went from 3p to 74p. Worth the risk in my opinion but everyone is entitled to decide for themselves.

George already told you it works. What more can you ask for.

This is not B & Q where you go to the shelf and sell items. 401 is one trial away from generating 15 million, 201 potential 65 million if it completes.

The strategy for the new compounds is to sell at the preclinical stage. The lab to help manage efficiency and costs. Not hard to understand but some don't get it.

It was and 201 was expected but never happened. The biotech stocks have all collapsed compared to what they were but also most of our assets have no value including the lab. We are just over 1 million but that is not what the company should be worth based on assets. Perhaps due to the cash situation but I would agree that we are in a similar situation where when we went from 3p to 74p obviously depending on whether they can deliver we might see a large turn. It all depends. Potential opportunity with risks but huge returns as well.

I do believe we have the best strategy on AIM but it only works well with a large market which is where we were a while back 30 million plus valuation in a bullish market with 201 confidence. If Valirx was 20/30 million and burning only 2 million bringing in evaluation projects and selling them at the preclinical stage for many millions and huge milestone payments then dilutions would be almost nothing with huge returns. The issue is that 201 went wrong and the economy changed.

Ok thanks, but that was the old board and obviously wrong what they did but it should not reflect on the current board.

Why it gets even more dangerous if you are funding clinical trials for a small company as larger sums are required to fund that. The strategy is still good but it takes time and It really needed 201 to get it going.

Who is this John Gilchrist?

Nothing unexpected to be fair. Bottom line they still need to deliver on 201 or 401 in the time they have left. Cash burn would have been around 150k region.

The Board believes that the combination of building the evaluation pipeline and additional sales and marketing initiatives for Inaphaea, together with prudent management of cash resources, including funds raised in the last placing, will bear fruit in the second half of 2024 and beyond.

Nonsense I post as a result of Porky and others constantly thrashing the company not the other way around. It can obviously double in fact do far more than that at this market cap if either 201 or 401 are signed. The issue here is the chat is always dominated by constant negativity where the majority of investors hide away.

Porky is always actively posting here even when I never posted for months. I have no interest in posting otherwise.

Does anyone know about development and production costs? Must be very high before any orders come through. Revenue next to nothing here nothing that really justifies such a high market cap.

I can see the market cap dropping to 5 million and a placing before we see a rise. As they say stay patient for the best rewards here. Costs are very high at the moment.

Surprised by the timing of the RNS today. As they often say bad news first then roll on the good news. Surely something big is on the way.

1) 201- If this was really not concluding then I see no reason why TRX would still be holding exclusivity therefore must be creditable. Expecting news shortly.

2) 401 - Deadline not far away to complete this deal. I like the Ambrose Healthcare website and the team behind that.

3) Evaluation outcome for StingyRay only a month away might come earlier.

Expecting some decent value adding news soon. 5/10p target by Christmas.

Revenue and other income of £0.24m (H1 2022/3: £0.02m)

· R&D spend of £1.9m (H1 2022/3: £2.0m)

· Operating loss of £2.4m (H1 2022/3: £2.7m)

· Cash of £1.2m as at 31 December 2023 (30 June 2023: £2.6m)

· Cash of £1.2m as at 20 March 2024 following recent receipt of R&D tax credit of £0.8m

Until you see revenue in the RNS then how is a market cap of 11 million justified? Potential deals but how much and where does it say the revenues will be many millions. It is all IFS and Buts nothing concrete. They would be burning considerably more than what they were previously.

Burning close to 600 k a month. The market cap of about 11 million without strong revenues is simply very inflated.

A large placing of about 8 million is likely imo to cover 12 months plus of cash. It will likely crash the share price and surely not far away.

Better to wait on the sidelines patiently as the market is horrible. Placing could be at 0.25p to 0.50p range then it might be a good time to buy. Just my opinion.

Flop.

Barcelona was a flow we all knew that if we followed from last year. StingRay is the promising one as mentioned by Cathy in the presentations. Only a month away.

Expecting 201 or 401 deal news shortly and that should take us to at least 5p.

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, has entered into an agreement with StingRay Bio Limited ("StingRay") to investigate a lead series of drug candidates for use in oncology.

The lead series of molecules has been developed by StingRay using a target-based drug design approach, to create novel candidate drugs for kinases with well-validated links to cancer. Under the agreement, the Company will carry out a defined series of preclinical tests on the molecules over the next twelve months to validate the technology and determine suitability for commercialisation.

This preclinical evaluation will investigate the action of the molecules against a range of cancer types. Research conducted at Inaphaea BioLabs and collaborative partners will progress lead optimisation of the lead series molecules and ascertain activity, utilising patient derived cells from the recently acquired Imagen biobank; as well as assessing safety profiles of lead candidates nominated from within the series.

The cost of the work will be borne by ValiRx and will be capped at £100,000 over the twelve month period. At the conclusion of the evaluation period the Company has an option to license the technology on pre-agreed terms.

Dr Suzy Dilly, CEO of ValiRx commented "It is hugely exciting to have another evaluation agreement commencing, particularly one such as this which has a high pedigree of medicinal chemistry behind it to build the lead series of molecules for us to continue its optimisation. I'm looking forward to working closely with the team at StingRay to continue the project."

Jeff Roix, CEO of Stingray Bio says, "We look forward to further progress in our evaluation agreement with ValiRx. With great innovation provided by its Inaphaea team and novel Imagen assets, we believe ValiRx's efforts can help realise the commercial potential of StingRay's founding contributions in new cancer therapeutics."